Regulatory affairs in medical devices is the function responsible for getting devices legally onto the market and keeping them there. It covers everything from classifying a product’s risk level and preparing government submissions to maintaining quality systems and monitoring the device after it reaches patients. In the U.S., this means satisfying the FDA. In Europe, it means meeting the EU Medical Device Regulation. Most companies selling globally must navigate both systems simultaneously, along with requirements in dozens of other countries.
What Regulatory Affairs Professionals Actually Do
At its core, the job is translating engineering and clinical work into the documentation that regulators require before a device can be sold. That starts early in product development, when someone needs to determine which regulatory pathway applies, and continues long after launch through ongoing safety reporting and quality audits.
The FDA requires medical device companies to meet a specific set of baseline obligations: registering their manufacturing facility, listing their devices, obtaining the right premarket clearance or approval, following quality management system rules, meeting labeling requirements, and reporting any safety problems through a process called Medical Device Reporting. Regulatory affairs teams own or coordinate nearly all of these activities. They also manage the equivalent requirements in other markets, each with its own rules and timelines.
Day to day, this can mean writing a 300-page submission for the FDA, coordinating a clinical study under an Investigational Device Exemption, preparing for a European audit, updating labeling to reflect a design change, or reviewing marketing materials to make sure claims stay within what’s been approved. The work is detail-heavy and deadline-driven, with significant consequences for mistakes. A poorly prepared submission can delay a product launch by months or years.
How the FDA Classifies Medical Devices
The FDA sorts every medical device into one of three classes based on the risk it poses to patients. This classification determines how much regulatory scrutiny a device faces before it can be sold.
- Class I covers the lowest-risk devices, things like tongue depressors, elastic bandages, and manual stethoscopes. Most are exempt from premarket review entirely, though they still must follow basic manufacturing and labeling rules (called general controls).
- Class II includes moderate-risk devices like powered wheelchairs, pregnancy tests, and surgical drapes. These require general controls plus additional “special controls,” which can include performance standards, postmarket surveillance, or specific labeling. Most Class II devices need a 510(k) clearance before they can be marketed.
- Class III covers the highest-risk devices: implantable pacemakers, heart valves, deep brain stimulators. These typically require a Premarket Approval (PMA), the most rigorous pathway, which demands clinical trial data proving safety and effectiveness.
A huge part of a regulatory affairs professional’s job is determining which class a new device falls into and, by extension, which submission pathway to follow. Getting this wrong can waste enormous time and money.
The Two Main U.S. Pathways: 510(k) and PMA
The 510(k) is the more common route. It requires a company to demonstrate that its device is “substantially equivalent” to a device already legally sold in the U.S. That means showing the new device has the same intended use and either the same technological characteristics or, if different, that it’s equally safe and effective. The FDA typically makes its determination within 90 days, though preparing the submission itself can take months of testing and documentation. The FDA charges a review fee, which varies by year and company size.
If the FDA decides a device is not substantially equivalent to anything on the market, the company has a few options: submit a new 510(k) with additional data, request a “De Novo” classification (essentially asking the FDA to create a new category for a novel low-to-moderate-risk device), or go through the full PMA process.
The PMA pathway is far more demanding. It requires valid scientific evidence, usually from clinical trials, that the device is safe and effective for its intended use. Review times are longer, costs are significantly higher, and the level of ongoing reporting after approval is more extensive. This is the path for devices like artificial hearts, implantable defibrillators, and other life-sustaining or life-supporting technologies.
Design Controls: Regulatory Work During Development
Regulatory affairs doesn’t begin when a device is finished. The FDA requires manufacturers to follow a structured process called design controls throughout development, and regulatory professionals help ensure these requirements are met from the start.
Design controls begin with design inputs: documenting what the device needs to do, based on user needs and intended use, in terms that can actually be measured. These feed into design outputs, which are the specifications, drawings, and documents that describe the final product. The key regulatory question at each stage is whether everything is traceable. Can you show that every user need maps to a specification, and that every specification was tested?
Two closely related but distinct steps come next. Design verification confirms the product was built correctly: does the output match the input? This typically involves bench testing and engineering analysis. Design validation confirms the right product was built: does it actually work for patients under real or simulated conditions? Validation must be performed on production-equivalent units, not prototypes. All of this documentation feeds into the Design History File, which regulators can inspect at any time.
Clinical Evidence and the Clinical Evaluation Report
Regulators need proof that a device is safe and performs as claimed, and that proof comes in the form of clinical evidence. In Europe, every device requires a Clinical Evaluation Report (CER), a comprehensive document that pulls together all available clinical data and analyzes whether it supports the device’s safety and performance claims.
The process follows four steps. First, the manufacturer creates a Clinical Evaluation Plan defining what needs to be demonstrated. Second, they identify all relevant clinical data, which can come from clinical trials of the device itself, published studies on equivalent devices, peer-reviewed literature, and postmarket surveillance data. Third, they critically appraise the quality and relevance of that data. Fourth, they synthesize it into a coherent argument that the device meets general safety and performance requirements.
A CER isn’t a one-time document. Manufacturers must update it throughout the device’s life, incorporating new safety data, postmarket clinical follow-up results, and any adverse events. For higher-risk devices, the clinical evidence bar is higher, and relying solely on literature from equivalent devices may not be sufficient.
Quality Management Systems and ISO 13485
Every medical device manufacturer needs a quality management system (QMS) that governs how they design, produce, and monitor their products. The international benchmark is ISO 13485:2016, a standard specifically written for medical device quality systems.
In a significant alignment move, the FDA issued a final rule in January 2024 amending its own quality system requirements to incorporate ISO 13485:2016 by reference. Previously, U.S. manufacturers had to comply with the FDA’s Quality System Regulation under 21 CFR 820, which overlapped with but didn’t match the international standard. Companies selling globally often maintained two parallel systems. The new rule reduces that burden by harmonizing the U.S. framework with what most other regulatory authorities already require.
Under the updated rule, the FDA can inspect management review records, internal quality audit reports, and supplier audit documentation. These records were already required by other regulators, so the FDA reasoned that making them available to U.S. inspectors wouldn’t create additional work for manufacturers. For regulatory affairs teams, this change means a single quality system can now serve multiple markets more efficiently, though the transition itself requires careful planning.
European Regulation and Key Deadlines
The European Union overhauled its medical device rules with the EU Medical Device Regulation (MDR), which replaced the older Medical Device Directives. The MDR significantly tightened requirements around clinical evidence, postmarket surveillance, and the oversight of Notified Bodies (the independent organizations that audit manufacturers and certify devices for the European market).
The transition has been long and, for much of the industry, painful. Deadlines have been extended multiple times because Notified Body capacity couldn’t keep pace with the volume of devices needing recertification. The current timeline looks like this:
- May 2024: Manufacturers of legacy devices had to lodge their MDR conformity assessment application and have a compliant quality management system in place.
- May 2026: Deadline for Class III custom-made implantable devices.
- December 2027: Transition ends for Class III and Class IIb implantable devices.
- December 2028: Transition ends for remaining Class IIb, Class IIa, and Class I sterile or measuring function devices.
For regulatory affairs professionals working in European markets, these deadlines define the workload for the next several years. Missing them means a device can no longer be sold in the EU.
Why It Matters Beyond Paperwork
Regulatory affairs is sometimes mischaracterized as a bureaucratic hurdle, but it shapes real commercial outcomes. A company that understands the regulatory landscape early can design its device, its clinical strategy, and its quality system to meet requirements from the start, avoiding costly redesigns or failed submissions. A company that treats regulation as an afterthought can spend years and millions of dollars stuck in review cycles.
The field is also growing more complex. Global markets increasingly require unique registrations, each with different classification rules, language requirements, and clinical evidence expectations. Software as a medical device, artificial intelligence, and combination products are creating entirely new regulatory questions. For anyone considering a career in the field or trying to understand what a regulatory affairs department does inside a medical device company, the short version is this: they are the people who make sure a device can legally reach the patients who need it, in every market where the company wants to sell.